Cargando…

Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?

INTRODUCTION: As the Coronavirus Disease 2019 (COVID-19) pandemic unfolds around the world; answers related to the antibody response against the virus are necessary to develop treatment and prophylactic strategies. We attempted to understand part of the immune response of convalescent plasma donatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Prudente, Tiago Paiva, Castro, Renato Gomes, Candido, Marcos Antonio, Rodrigues, Roberta Luiza, de Souza, Layane Marques, Roberti, Maria do Rosario Ferraz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566374/
https://www.ncbi.nlm.nih.gov/pubmed/34751255
http://dx.doi.org/10.1016/j.htct.2021.07.008
_version_ 1784593997630537728
author Prudente, Tiago Paiva
Castro, Renato Gomes
Candido, Marcos Antonio
Rodrigues, Roberta Luiza
de Souza, Layane Marques
Roberti, Maria do Rosario Ferraz
author_facet Prudente, Tiago Paiva
Castro, Renato Gomes
Candido, Marcos Antonio
Rodrigues, Roberta Luiza
de Souza, Layane Marques
Roberti, Maria do Rosario Ferraz
author_sort Prudente, Tiago Paiva
collection PubMed
description INTRODUCTION: As the Coronavirus Disease 2019 (COVID-19) pandemic unfolds around the world; answers related to the antibody response against the virus are necessary to develop treatment and prophylactic strategies. We attempted to understand part of the immune response of convalescent plasma donation candidates. METHOD: We carried out a cross-sectional, observational, non-intervention study, testing 102 convalescent plasma donation candidates for antibodies against the virus, relating these data to the time interval between symptom onset and sample collection, age, disease severity, and gender. RESULTS: In our sample, the individuals who developed a greater antibody response were the ones who had a longer time interval between symptom onset and sample collection, the ones who had been hospitalized and the subjects above 35 years old. Moreover, 17 individuals did not present any reactive antibodies. CONCLUSION: These results are important in that they raise questions about the role of the humoral response against the virus, as some individuals do not develop antibodies to fight it. In addition, they help develop recruitment strategies for convalescent plasma donors, who should be asymptomatic for at least 21 days and are possibly more likely to have reactive antibodies after 35 days without symptoms.
format Online
Article
Text
id pubmed-8566374
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sociedade Brasileira de Hematologia e Hemoterapia
record_format MEDLINE/PubMed
spelling pubmed-85663742021-11-04 Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility? Prudente, Tiago Paiva Castro, Renato Gomes Candido, Marcos Antonio Rodrigues, Roberta Luiza de Souza, Layane Marques Roberti, Maria do Rosario Ferraz Hematol Transfus Cell Ther Original Article INTRODUCTION: As the Coronavirus Disease 2019 (COVID-19) pandemic unfolds around the world; answers related to the antibody response against the virus are necessary to develop treatment and prophylactic strategies. We attempted to understand part of the immune response of convalescent plasma donation candidates. METHOD: We carried out a cross-sectional, observational, non-intervention study, testing 102 convalescent plasma donation candidates for antibodies against the virus, relating these data to the time interval between symptom onset and sample collection, age, disease severity, and gender. RESULTS: In our sample, the individuals who developed a greater antibody response were the ones who had a longer time interval between symptom onset and sample collection, the ones who had been hospitalized and the subjects above 35 years old. Moreover, 17 individuals did not present any reactive antibodies. CONCLUSION: These results are important in that they raise questions about the role of the humoral response against the virus, as some individuals do not develop antibodies to fight it. In addition, they help develop recruitment strategies for convalescent plasma donors, who should be asymptomatic for at least 21 days and are possibly more likely to have reactive antibodies after 35 days without symptoms. Sociedade Brasileira de Hematologia e Hemoterapia 2022 2021-11-04 /pmc/articles/PMC8566374/ /pubmed/34751255 http://dx.doi.org/10.1016/j.htct.2021.07.008 Text en © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Prudente, Tiago Paiva
Castro, Renato Gomes
Candido, Marcos Antonio
Rodrigues, Roberta Luiza
de Souza, Layane Marques
Roberti, Maria do Rosario Ferraz
Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
title Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
title_full Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
title_fullStr Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
title_full_unstemmed Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
title_short Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
title_sort antibody response against sars-cov-2 in convalescent plasma donors: can we predict subjects’ eligibility?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566374/
https://www.ncbi.nlm.nih.gov/pubmed/34751255
http://dx.doi.org/10.1016/j.htct.2021.07.008
work_keys_str_mv AT prudentetiagopaiva antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility
AT castrorenatogomes antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility
AT candidomarcosantonio antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility
AT rodriguesrobertaluiza antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility
AT desouzalayanemarques antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility
AT robertimariadorosarioferraz antibodyresponseagainstsarscov2inconvalescentplasmadonorscanwepredictsubjectseligibility